EAM Investors LLC Makes New $786,000 Investment in Chimerix, Inc. (NASDAQ:CMRX)

EAM Investors LLC bought a new stake in shares of Chimerix, Inc. (NASDAQ:CMRX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 225,777 shares of the biopharmaceutical company's stock, valued at approximately $786,000. EAM Investors LLC owned about 0.25% of Chimerix at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of CMRX. Walleye Capital LLC bought a new stake in shares of Chimerix in the fourth quarter valued at about $1,362,000. Rosalind Advisors Inc. acquired a new stake in shares of Chimerix during the 4th quarter worth approximately $10,614,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Chimerix by 24.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,513 shares of the biopharmaceutical company's stock valued at $1,495,000 after purchasing an additional 84,801 shares during the period. Bender Robert & Associates acquired a new position in shares of Chimerix in the fourth quarter valued at $37,000. Finally, Charles Schwab Investment Management Inc. bought a new position in Chimerix in the fourth quarter worth $183,000. 45.42% of the stock is owned by institutional investors.

Chimerix Price Performance

NASDAQ:CMRX remained flat at $8.54 during trading hours on Tuesday. The firm has a market cap of $801.09 million, a P/E ratio of -9.09 and a beta of -0.17. The company has a fifty day simple moving average of $7.47 and a 200-day simple moving average of $4.07. Chimerix, Inc. has a twelve month low of $0.75 and a twelve month high of $8.55.

Chimerix (NASDAQ:CMRX - Get Free Report) last announced its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million. On average, analysts anticipate that Chimerix, Inc. will post -0.99 EPS for the current year.

Wall Street Analysts Forecast Growth

CMRX has been the subject of a number of recent research reports. Wedbush restated a "neutral" rating and issued a $8.55 price objective (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. Jefferies Financial Group reaffirmed a "hold" rating and set a $8.50 price objective (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com began coverage on shares of Chimerix in a research note on Wednesday, April 16th. They issued a "hold" rating for the company. Finally, HC Wainwright reiterated a "neutral" rating and issued a $8.55 price objective (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Insiders Place Their Bets

In related news, CEO Michael T. Andriole sold 7,370 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last 90 days, insiders sold 20,760 shares of company stock valued at $91,175. Company insiders own 13.10% of the company's stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.